electroCore, Inc. announced that Ascent Health Services on behalf of Express Scripts has elected to make gammaCoreTM a preferred brand on all of its Standard National Formularies for those benefit designs that do not differentiate between drugs and devices at a monthly co-pay of roughly $25- $45. gammaCore is electroCore’s non-invasive vagus nerve stimulation (nVNS) device that is FDA-cleared for the adjunctive use for the preventive treatment of cluster headache, and the acute treatment of pain associated with cluster and migraine headache in adults. gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy FDA-cleared as an adjunctive therapy for the preventative treatment of cluster headache and as an acute treatment for pain associated with episodic cluster headache and migraine headache in adult patients. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers leading to a modulation of neurotransmitters and a reduction in pain. gammaCore is the only therapy FDA-cleared for the prevention of cluster headache. gammaCore is available by prescription only and patients should speak with their doctor about whether gammaCore is right for them. gammaCore™ (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore is indicated for: Adjunctive use for the preventive treatment of cluster headache in adult patients. The acute treatment of pain associated with episodic cluster headache in adult patients. The acute treatment of pain associated with migraine headache in adult patients. The safety and effectiveness of gammaCore (nVNS) have not been established in the acute treatment of chronic cluster headache. gammaCore has not been shown to be effective for the preventive treatment of migraine headache. The long-term effects of the chronic use of gammaCore have not been evaluated. Safety and efficacy of gammaCore have not been evaluated in the following patients, and therefore it is NOT indicated for: Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device. Patients diagnosed with narrowing of the arteries (carotid atherosclerosis). Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy). Pediatric patients. Pregnant women. Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia. Patients should not use gammaCore if they: Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck. Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone).